News & Events about Abcellera Biologics Inc.
AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023...
AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV). The partnership aims to provide...
Cowen assumed coverage on shares of AbCellera Biologics (NASDAQ:ABCL Get Rating) in a research report released on Tuesday, Marketbeat reports. The firm issued an outperform rating on the stock. Other research analysts have also issued research reports about the company. The Goldman Sachs ...
AbCellera Biologics Inc. (NASDAQ:ABCL Get Rating) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 15,350,000 shares, a decline of 7.0% from the November 30th total of 16,510,000 shares. ...
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCelleras antibody...